Atto vastatin reduces the risk of liver tumor in patients with viral and metabolic liver disease and inhibits YAP1 activation; Simvastatin was used as a YAP1 inhibitor and was found to target YAP1 in combination with sorafenib or trametinib; Cerivastatin and simvastatin regulate the localization of YAP1 protein in HCC cells by inhibiting senescence junction and Rho GTP enzyme-mediated cytoskeleton remodeling involved in the migration and transfer of HCC. The gene discussed is YAP1; the disease is hepatocellular carcinoma.